Sara Cuevas Ocana

Dr. Sara Cuevas Ocana

Biodiscovery Institute, Medical School, University of Nottingham
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in JHEP Reports
Verified
Journal Article
Open access
JGJane Grove
Jane Grove
PLPeggy C.K. Lo
Peggy C.K. Lo
NSNick Shrine
Nick Shrine
JBJulian Barwell
Julian Barwell
LWLouise V. Wain
Louise V. Wain
GAGuruprasad Aithal
Guruprasad Aithal
Non-alcoholic fatty liver disease (NAFLD) is a complex trait with an estimated prevalence of 25% globally. We aimed to identify the genetic variant underlying a four-generation family with progressive NAFLD leading to cirrhosis, decompensation, and development of hepatocellular carcinoma in the absence of common risk factors such as obesity and type 2 diabetes. Exome sequencing and genome comparisons were used to identify the likely causal variant. We extensively characterised the clinical phenotype and post-prandial metabolic responses of family members with the identified novel variant in comparison with healthy non-carriers and wild-type patients with NAFLD. Variant-expressing hepatocyte-like cells (HLCs) were derived from human-induced pluripotent stem cells generated from homozygous donor skin fibroblasts and restored to wild-type using CRISPR-Cas9. The phenotype was assessed using imaging, targeted RNA analysis, and molecular expression arrays. We identified a rare causal variant c.1691T>C p.I564T (rs745447480) in MTTP, encoding microsomal triglyceride transfer protein (MTP), associated with progressive NAFLD, unrelated to metabolic syndrome and without characteristic features of abetalipoproteinaemia. HLCs derived from a homozygote donor had significantly lower MTP activity and lower lipoprotein ApoB secretion than wild-type cells, while having similar levels of MTP mRNA and protein. Cytoplasmic triglyceride accumulation in HLCs triggered endoplasmic reticulum stress, secretion of pro-inflammatory mediators, and production of reactive oxygen species. We have identified and characterised a rare causal variant in MTTP, and homozygosity for MTTP p.I564T is associated with progressive NAFLD without any other manifestations of abetalipoproteinaemia. Our findings provide insights into mechanisms driving progressive NAFLD. A rare genetic variant in the gene MTTP has been identified as responsible for the development of severe non-alcoholic fatty liver disease in a four-generation family with no typical disease risk factors. A cell line culture created harbouring this variant gene was characterised to understand how this genetic variation leads to a defect in liver cells, which results in accumulation of fat and processes that promote disease. This is now a useful model for studying the disease pathways and to discover new ways to treat common types of fatty liver disease.

Verified
Journal Article
Open access
PDF file
SOSara Cuevas Ocana
Sara Cuevas Ocana
JYJin Ye Yang
Jin Ye Yang
MAMagomet Aushev
Magomet Aushev
GSGeorge Schlossmacher
George Schlossmacher
CBChristine Bear
Christine Bear
Michael GrayMichael Gray
Michael Gray
Introducing or correcting disease-causing mutations through genome editing in human pluripotent stem cells (hPSCs) followed by tissue-specific differentiation provide sustainable models of multiorgan diseases, such as cystic fibrosis (CF). However, low editing efficiency resulting in extended cell culture periods and the use of specialised equipment for fluorescence activated cell sorting (FACS) make hPSC genome editing still challenging. We aimed to investigate whether a combination of cell cycle synchronisation, single-stranded oligodeoxyribonucleotides, transient selection, manual clonal isolation, and rapid screening can improve the generation of correctly modified hPSCs. Here, we introduced the most common CF mutation, ΔF508, into the CFTR gene, using TALENs into hPSCs, and corrected the W1282X mutation using CRISPR-Cas9, in human-induced PSCs. This relatively simple method achieved up to 10% efficiency without the need for FACS, generating heterozygous and homozygous gene edited hPSCs within 3–6 weeks in order to understand genetic determinants of disease and precision medicine.

1 April 2025 in Breathe
Verified
Journal Article
Open access
PDF file
EVEirini Vasarmidi
Eirini Vasarmidi
JWJulie C. Worrell
Julie C. Worrell
Irma Mahmutovic PerssonIrma Mahmutovic Persson
Irma Mahmutovic Persson
NYNaheem Yaqub
Naheem Yaqub
EMEwa Miądlikowska
Ewa Miądlikowska
SOSara Cuevas Ocana
Sara Cuevas Ocana
This review summarises some of the key features of interstitial lung diseases (ILDs) from a translational science point of view and brings insights into potential therapeutic options. Genetic predisposition and environmental factors like smoking, pollution and infections significantly impact the onset, progression and treatment response in ILDs, highlighting the need for personalised management. Fibroblasts are central to ILD pathology, influencing the tissue microenvironment, immune cell interactions and extracellular matrix (ECM) production, making them critical therapeutic targets. Monocyte-derived M2 macrophages drive fibrosis in idiopathic pulmonary fibrosis by secreting cytokines and remodelling the ECM. Understanding macrophage subtypes and their dynamics offers new therapeutic possibilities. Chronic type 2 immunity contributes to fibrosis, emphasising the need to enhance protective markers in order to even out the balance shift of pathological immune responses in ILD treatments. Serum biomarkers like Krebs von den Lungen-6 (KL-6), surfactant protein (SFTP) D, matrix metalloproteinase-7 (MMP-7), and C-C motif chemokine ligand (CCL)-18 are valuable for diagnosing and predicting ILD progression, although more research is needed for clinical application. Animal models, especially bleomycin-based models, offer insights into ILD pathology, but challenges like lung hyperinflation highlight the need for careful model selection and translational research to bridge preclinical and clinical findings.

13 June 2023 in Breathe
Verified
Journal Article
Open access
PDF file
JPJames Parkin
James Parkin
JDJustine Devulder
Justine Devulder
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
NUNiki Ubags
Niki Ubags
MPMaxime Patout
Maxime Patout
JCJoana Cruz
Joana Cruz
This article provides testimonials of the past and current chairs and co-chairs of the ECMC (@EarlyCareerERS) and a glimpse of the NEXT programme, along with participants’ experiences. https://bit.ly/3LzvqKf

1 March 2024 in Breathe
Verified
Journal Article
Open access
PDF file
SMSilke Meiners
Silke Meiners
NRNiki L. Reynaert
Niki L. Reynaert
AMAndreas M. Matthaiou
Andreas M. Matthaiou
RRRishi Rajesh
Rishi Rajesh
EAEngi Ahmed
Engi Ahmed
SOSara Cuevas Ocana
Sara Cuevas Ocana
The Translational Science Working Group at the European Respiratory Society (ERS) aims to bridge the gap between basic and clinical science by providing a platform where scientists, clinicians and experts in the respiratory field can actively shape translational research. For the 2023 Congress, dedicated translational science sessions were created and sessions of interest to many assemblies from the clinical and the scientific point of view were tagged as translational sessions, attracting clinical and scientific experts to the same room to discuss relevant topics and strengthening translational efforts among all ERS assemblies.

30 November 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
KRKarosham Diren Reddy
Karosham Diren Reddy
Nikoleta BizymiNikoleta Bizymi
Nikoleta Bizymi
ASAnja Schweikert
Anja Schweikert
SASachin Ananth
Sachin Ananth
CLClarice X. Lim
Clarice X. Lim
SOSara Cuevas Ocana
Sara Cuevas Ocana
Early career members of Assembly 3 (Basic and Translational Sciences) of the European Respiratory Society (ERS) summarise the key messages discussed during six selected sessions that took place at the ERS International Congress 2023 in Milan, Italy. Aligned with the theme of the congress, the first session covered is “Micro- and macro-environments and respiratory health”, which is followed by a summary of the “Scientific year in review” session. Next, recent advances in experimental methodologies and new technologies are discussed from the “Tissue modelling and remodelling” session and a summary provided of the translational science session, “What did you always want to know about omics analyses for clinical practice?”, which was organised as part of the ERS Translational Science initiative's aims. The “Lost in translation: new insights into cell-to-cell crosstalk in lung disease” session highlighted how next-generation sequencing can be integrated with laboratory methods, and a final summary of studies is presented from the “From the transcriptome landscape to innovative preclinical models in lung diseases” session, which links the transcriptome landscape with innovative preclinical models. The wide range of topics covered in the selected sessions and the high quality of the research discussed demonstrate the strength of the basic and translational science being presented at the international respiratory conference organised by the ERS.